Lavipharm S.A. Logo

Lavipharm S.A.

Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.

LAVI | AT

Overview

Corporate Details

ISIN(s):
GRS246003008
LEI:
213800USC69CRPRGWJ15
Country:
Greece
Address:
AGIAS MARINAS STR, 19002 PAIANIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lavipharm S.A. is an integrated international healthcare company focused on the research, development, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements and cosmetics. Lavipharm provides innovative treatment options to healthcare professionals, concentrating on key therapeutic areas such as cardiology, neurology (CNS), urology, oncology, and chronic pain. The company manages the entire value chain, from initial research and development to commercial sales and distribution.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 11:56
Regulatory News Service
Ανακοίνωση Τροποποίησης προγράμματος stock options
Greek (modern) 4.8 MB
2025-09-18 19:39
Interim Report
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Εξαμηνιαία,Ενοποιημένη)
Greek (modern) 2.2 MB
2025-09-18 16:50
Earnings Release
ΔΕΛΤΙO ΤΥΠΟΥ ΟΙΚΟΝΟΜΙΚΑ ΑΠΟΤΕΛΕΣΜΑΤΑ Α΄ ΕΞΑΜΗΝΟΥ 2025
Greek (modern) 156.3 KB
2025-09-18 16:50
Earnings Release
FINANCIAL RESULTS PRESS RELEASE FIRST HALF 2025
English 99.2 KB
2025-07-10 09:38
Registration Form
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορ…
Greek (modern) 216.3 KB
2025-07-09 09:52
Share Issue/Capital Change
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορ…
Greek (modern) 205.1 KB
2025-07-03 18:12
Notice of Dividend Amount
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤ…
Greek (modern) 555.0 KB
2025-07-03 18:00
Post-Annual General Meeting Information
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 123.4 KB
2025-07-03 18:00
Post-Annual General Meeting Information
PRESS RELEASE
English 121.3 KB
2025-07-03 17:35
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
Greek (modern) 503.0 KB
2025-07-03 17:17
Board/Management Information
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΛΛΑΓΗΣ ΣΥΝΘΕΣΗΣ ΔΙΟΙΚΗΤΙΚΟΥ ΣΥΜΒΟΥΛΙΟΥ
Greek (modern) 598.1 KB
2025-07-03 17:05
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 195.1 KB
2025-06-11 16:30
Pre-Annual General Meeting Information
ΠΡΟΣΚΛΗΣΗ ΣΕ ΤΑΚΤΙΚΗ ΓΕΝΙΚΗ ΣΥΝΕΛΕΥΣΗ
Greek (modern) 191.0 KB
2025-05-15 16:19
Earnings Release
Βασικά Οικονομικά Μεγέθη A Τριμήνου 2025
Greek (modern) 118.2 KB
2025-05-15 16:19
Earnings Release
Financial Results Q1 2025
English 92.6 KB

Automate Your Workflow. Get a real-time feed of all Lavipharm S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lavipharm S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lavipharm S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France
ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.